Intercept Pharmaceuticals, Inc.
Farnesoid x receptor modulators

Last updated:

Abstract:

The present invention provides a compound of formula (I): ##STR00001## or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.

Status:
Grant
Type:

Utility

Filling date:

26 Nov 2019

Issue date:

11 May 2021